Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646 1647 1654 1674
This examiner grants 64% of resolved cases
Bridget E. Bunner is an examiner in Tech Center 1600 and Art Unit 1644. She has 839 resolved cases, resulting in an allowance rate pct of 64.5. This indicates that a majority of the applications she reviews reach allowance. The median days to allowance for these cases is 1043, providing a timeline for the expected duration of the prosecution cycle from filing to grant.
The interview lift pct of 19.9 is a notable metric. It indicates that interviews are effective and correlate with an increase in the probability of allowance. For practitioners in Art Unit 1644, the 19.9 interview lift pct highlights the value of oral advocacy in resolving rejections and securing a grant from the 839 resolved cases. This lift is a useful indicator of examiner receptivity.
The 64.5 allowance rate pct and the 1043 median days to allowance define a favorable environment for applicants. The 19.9 interview lift pct provides a tool for further improving success. Applicants should consider the 839 resolved cases as evidence of a consistent examination style where interviews play a role in achieving the 64.5 allowance rate pct in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18439951 | METHODS FOR TREATING MULTIPLE MYELOMA | Non-Final OA | Janssen Biotech, Inc. |
| 18283575 | METHODS AND AGENTS FOR MODULATING ADOPTIVE IMMUNOTHERAPY | Non-Final OA | The Regents of the University of California |
| 18263929 | TREATMENT OF CVD AND SYSTEMIC SCEROSIS WITH BETA-1 ADRENERGIC RECEPTOR ANTIBODIES | Non-Final OA | The Cleveland Clinic Foundation |
| 18034326 | USE OF AN IL-18 ANTAGONIST FOR TREATING AND/OR PREVENTION OF ATOPIC DERMATITIS OR A RELATED CONDITION | Non-Final OA | NOVARTIS AG |
| 17877814 | COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES, SECRETED BIOMOLECULES, AND/OR CONDITIONED MEDIA, AND METHODS OF PRODUCING AND USING THE SAME | Final Rejection | L'Oreal |
| 18442988 | BTLA Fusion Protein Agonists and Uses Thereof | Non-Final OA | PFIZER INC. |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 17767810 | Artificial Transmembrane Proteins for Detecting Intracellular or Intravesicular Biomolecular Interactions | Final Rejection | Hoffmann-La Roche Inc. |
| 18408385 | T-CELLS COMPRISING ANTI-CD38 AND ANTI-CD138 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Non-Final OA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18297805 | SOLUBLE TREM2 PROTEIN AND USES THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | Non-Final OA | MedImmune Limited |
| 18035356 | Methods and compositions for eliminating engineered immune cells | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18001480 | IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX | Non-Final OA | MONASH UNIVERSITY |
| 18299480 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
| 17750444 | PROTEIN PURIFICATION | Non-Final OA | UCB PHARMA, S.A. |
| 16958624 | DUAL-ACTIVATING COSTIMULATORY MOLECULE RECEPTOR AND USE THEREOF | Final Rejection | Shanghai Cell Therapy Group Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy